RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BridgeBio Pharma Stock

BridgeBio Pharma ROE 2025

BridgeBio Pharma ROE

0.47

Ticker

BBIO

ISIN

US10806X1028

WKN

A2PLX7

In 2025, BridgeBio Pharma's return on equity (ROE) was 0.47, a 23.84% increase from the 0.38 ROE in the previous year.

BridgeBio Pharma Aktienanalyse

What does BridgeBio Pharma do?

BridgeBio Pharma Inc. is a US biotech company founded in 2015. The company is based in Palo Alto, California and specializes in researching and developing medications for rare diseases. BridgeBio's business model is based on a pipeline of rare diseases that have little or no existing treatment options. The company identifies, finances, and operates individual independent subsidiary companies with the goal of developing precision medicines for rare and genetic diseases. An important element of BridgeBio's business strategy is strategic collaboration with academic institutions and other companies to share research and development expertise. BridgeBio has various subsidiary companies, each specializing in the development of medications for a specific genetic disease. These include Eidos Therapeutics, QED Therapeutics, PellePharm, Navire Pharma, Origin Biosciences, CoA Therapeutics, Calcilytix Therapeutics, Phoenix Tissue Repair, and MyoKardia. Eidos Therapeutics is constantly searching for therapies for transthyretin-mediated amyloidosis (ATTR), a rare cardiovascular disease caused by the buildup of amyloid proteins in various parts of the body. The first FDA-approved eprodisate therapy became available in Japan in 2005, making Eidos Therapeutics one of the most promising subsidiary companies of BridgeBio. QED Therapeutics specializes in developing therapies for Gorlin syndrome and medulloblastoma, a type of brain tumor. PellePharm aims to develop a topical therapy for Gorlin syndrome that can be used to control and treat tumors and non-tumorous skin changes. Navire Pharma explores specific kinases that influence cell growth and cell death signaling pathways to identify healing methods for cancer patients. Calcilytix Therapeutics focuses on discovering a treatment solution for chronic kidney diseases, with a main focus on stopping or reducing the loss of kidney function. Overall, BridgeBio is dedicated to the development of precision medicines designed to combat the underlying genetic causes of rare diseases. The company also advances the field of precision medicine and works closely with doctors and patients to improve the diagnosis of rare diseases and optimize patient care. In 2019, BridgeBio Pharma announced a strategic partnership with the Pharmaceutical Research and Manufacturers of America (PhRMA). The goal of this collaboration is to improve awareness of rare diseases and create better access to new medications. BridgeBio hopes that the partnership will accelerate the development of therapies for rare diseases. In conclusion, BridgeBio Pharma Inc. is an innovative biotech company specializing in the development of precision medicines for the treatment of rare genetic diseases. With a business model based on collaboration with subsidiary companies and strategic partners, BridgeBio Pharma Inc. aims to revolutionize the treatment and cure of patients with rare genetic diseases. BridgeBio Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding BridgeBio Pharma's Return on Equity (ROE)

BridgeBio Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing BridgeBio Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

BridgeBio Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in BridgeBio Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about BridgeBio Pharma stock

What is the ROE (Return on Equity) of BridgeBio Pharma this year?

The ROE of BridgeBio Pharma this year is 0.47 undefined.

How has the Return on Equity (ROE) of BridgeBio Pharma developed compared to the previous year?

The ROE of BridgeBio Pharma has increased by 23.84% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of BridgeBio Pharma?

A high ROE indicates that BridgeBio Pharma generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of BridgeBio Pharma?

A low ROE can indicate that BridgeBio Pharma is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of BridgeBio Pharma affect the company?

A change in ROE (Return on Equity) of BridgeBio Pharma can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of BridgeBio Pharma?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of BridgeBio Pharma?

Some factors that can influence BridgeBio Pharma's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does BridgeBio Pharma pay?

Over the past 12 months, BridgeBio Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BridgeBio Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of BridgeBio Pharma?

The current dividend yield of BridgeBio Pharma is .

When does BridgeBio Pharma pay dividends?

BridgeBio Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BridgeBio Pharma?

BridgeBio Pharma paid dividends every year for the past 0 years.

What is the dividend of BridgeBio Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BridgeBio Pharma located?

BridgeBio Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von BridgeBio Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BridgeBio Pharma from 1/4/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/4/2025.

When did BridgeBio Pharma pay the last dividend?

The last dividend was paid out on 1/4/2025.

What was the dividend of BridgeBio Pharma in the year 2024?

In the year 2024, BridgeBio Pharma distributed 0 USD as dividends.

In which currency does BridgeBio Pharma pay out the dividend?

The dividends of BridgeBio Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von BridgeBio Pharma

Our stock analysis for BridgeBio Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BridgeBio Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.